Researchers argued in a medical journal that low-risk prostate cancer should be relabeled to reduce unnecessary anxiety and overtreatment among newly diagnosed patients. The proposal addresses psychological harm from the word cancer attached to indolent lesions.
Active surveillance has become standard for many low-grade prostate tumors that grow slowly and may never threaten life. Despite this, the cancer label prompts some patients to pursue surgery or radiation with significant side effects.
Renaming conventions exist in other specialties where terminology change reduced overtreatment, such as ductal carcinoma in situ debates in breast oncology. Prostate cancer nomenclature revision would require consensus among urologists, pathologists, and patient advocates.
Authors emphasized that relabeling applies only to verified low-risk disease, not aggressive tumors requiring prompt intervention. The journal commentary aims to spark guideline discussions about patient communication and treatment thresholds.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.medscape.com/